In this exploratory study, we found that PAX1 methylation could be a promising auxiliary marker in the prediction of pathological upgrade risk in patients with CIN2 or CIN3 before conization, especially if △CpPAX1 cut-off value is lower than 6.360, as we found this to be highly suggestive of invasive cervical cancer. This evidence concerns the gene PAX1 and cervical cancer.